SAN FRANCISCO, Oct. 18 – Contending patent violations, Invitrogen filed suit against Incyte Genomics Wednesday in the US District Court of Delaware, Invitrogen told GenomeWeb .

The primary patent in contention is Invitrogen’s SuperScript form of RNAse H minus reverse transcriptase, which Invitrogen said was sold to Incyte under a research-use-only license.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.